Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early Alzheimer's Patients

NCT06432166 is registered in ClinicalTrials.gov with MTI Biotech Inc as lead sponsor.

NCT NCT06432166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06432166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early Alzheimer's Patients
Lead sponsor
MTI Biotech Inc
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
June 30, 2029
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment